Given the safety, early efficacy, and correlatives indicating enhancement of neoepitope-specific T cell responses we observed following treatment with bintrafusp alfa, future HNSCC clinical studies assessing whether similar findings are observed following PD-(L)1 blockade without TGF-β neutralization are warranted. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.